Patient experience surveys will be administered prospectively throughout the study period, whereas the review of patients' medical records will be conducted retrospectively towards the end of the study period.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).
Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA.
Participant is aged 18 years or older at enrolment.
You may not be if
Participation in a clinical trial at enrolment.
Clareo Health | Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
